Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
EXAS 
EXACT Sciences Corporation (EXAS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: EXAS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
26 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $62.97
1 Year Target Price $62.97
| 17 | Strong Buy |
| 6 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -24.42% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.98B USD | Price to earnings Ratio - | 1Y Target Price 62.97 |
Price to earnings Ratio - | 1Y Target Price 62.97 | ||
Volume (30-day avg) 26 | Beta 0.93 | 52 Weeks Range 38.81 - 72.83 | Updated Date 08/29/2025 |
52 Weeks Range 38.81 - 72.83 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.45 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate -0.13 | Actual -0.01 |
Profitability
Profit Margin -34.19% | Operating Margin (TTM) 0.34% |
Management Effectiveness
Return on Assets (TTM) -1.39% | Return on Equity (TTM) -35.51% |
Valuation
Trailing PE - | Forward PE 2500 | Enterprise Value 10551554214 | Price to Sales(TTM) 3.05 |
Enterprise Value 10551554214 | Price to Sales(TTM) 3.05 | ||
Enterprise Value to Revenue 3.59 | Enterprise Value to EBITDA 215.11 | Shares Outstanding 189319008 | Shares Floating 187461890 |
Shares Outstanding 189319008 | Shares Floating 187461890 | ||
Percent Insiders 0.91 | Percent Institutions 95.57 |
Upturn AI SWOT
EXACT Sciences Corporation
Company Overview
History and Background
EXACT Sciences Corporation was founded in 1995. Initially focused on various diagnostic technologies, it pivoted to specialize in colorectal cancer screening with Cologuard. It has grown through organic development and acquisitions to become a leader in cancer diagnostics.
Core Business Areas
- Screening: Focuses on early cancer detection, primarily through Cologuard for colorectal cancer screening. This includes testing kits and related services.
- Precision Oncology: Involves genomic testing to guide cancer treatment decisions. This includes tests like Oncotype DX for breast cancer and other tumor profiling services.
Leadership and Structure
The leadership team includes Kevin Conroy (Chairman & CEO). The organizational structure is functional, with departments focused on R&D, sales & marketing, operations, and finance.
Top Products and Market Share
Key Offerings
- Cologuard: A non-invasive stool DNA screening test for colorectal cancer. It's a leading product in its category. Analysts estimate Cologuard brings in the majority of the company's revenue. Competitors include traditional colonoscopies and fecal immunochemical tests (FITs). Exact Sciences dominates the stool DNA test market.
- Oncotype DX: A genomic test that analyzes tumor samples to predict the likelihood of cancer recurrence and guide treatment decisions. It is used primarily for breast cancer. Competitors include other genomic profiling services like those offered by Genomic Health (acquired by Exact Sciences) and Foundation Medicine (owned by Roche).
Market Dynamics
Industry Overview
The cancer diagnostics industry is growing due to an aging population, increased awareness of early detection, and advancements in genomic testing. The industry is highly competitive and regulated.
Positioning
EXACT Sciences is a leader in non-invasive cancer screening and genomic testing. Its competitive advantages include its established Cologuard brand, its strong sales force, and its intellectual property portfolio.
Total Addressable Market (TAM)
The colorectal cancer screening TAM is estimated to be over $20 billion, and the overall cancer diagnostics market is significantly larger. Exact Sciences is well-positioned to capture a significant share of this market, focusing on expanding screening rates and precision oncology.
Upturn SWOT Analysis
Strengths
- Strong brand recognition (Cologuard)
- Established sales and marketing infrastructure
- Proprietary technology and intellectual property
- Leading position in colorectal cancer screening market
- Presence in Precision Oncology
Weaknesses
- Reliance on a single key product (Cologuard)
- High marketing and sales expenses
- Negative profitability historically
- Susceptibility to changes in screening guidelines
- Dependence on favorable reimbursement rates
Opportunities
- Expanding Cologuard's market share through increased awareness and adoption
- Developing new diagnostic tests and expanding into other cancer types
- Leveraging data analytics to improve test performance
- Partnerships with healthcare providers and payers
- Acquiring complementary technologies and businesses
Threats
- Increased competition from established diagnostic companies
- Changes in screening guidelines that could reduce demand for Cologuard
- Unfavorable reimbursement rates from payers
- Regulatory hurdles and potential delays in new product approvals
- Technological disruptions
Competitors and Market Share
Key Competitors
- BIIB
- HOLX
- DGX
Competitive Landscape
EXACT Sciences benefits from its brand recognition and focus on colorectal cancer screening. However, it faces competition from established diagnostic companies with broader portfolios. Its success depends on continued innovation, effective marketing, and favorable reimbursement policies.
Major Acquisitions
Genomic Health
- Year: 2019
- Acquisition Price (USD millions): 2800
- Strategic Rationale: Expanded Exact Sciences' presence in precision oncology with the Oncotype DX test.
PreventionGenetics
- Year: 2021
- Acquisition Price (USD millions): 190
- Strategic Rationale: Added capabilities in hereditary cancer testing.
Growth Trajectory and Initiatives
Historical Growth: EXACT Sciences has experienced rapid growth in revenue and market capitalization over the past decade, driven by the success of Cologuard and strategic acquisitions.
Future Projections: Analysts predict continued revenue growth for EXACT Sciences, driven by increasing Cologuard adoption, expansion into new markets, and growth in the precision oncology segment. Profitability is expected to improve over time.
Recent Initiatives: Recent initiatives include expanding Cologuard's marketing efforts, developing new diagnostic tests for other cancers, and integrating acquired businesses.
Summary
EXACT Sciences is a leading cancer diagnostics company with significant growth potential, mainly attributed to its Cologuard product. Its strong brand recognition and effective marketing are strengths. However, it relies heavily on Cologuard and faces profitability challenges, needing diversification and optimized expense management to maintain its competitive edge and achieve sustained financial success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Analyst Reports
- Company Investor Relations
- Industry Reports
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About EXACT Sciences Corporation
Exchange NASDAQ | Headquaters Madison, WI, United States | ||
IPO Launch date 2001-02-01 | Chairman of the Board & CEO Mr. Kevin T. Conroy J.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 6900 | Website https://www.exactsciences.com |
Full time employees 6900 | Website https://www.exactsciences.com | ||
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.